RIGL — RIGEL PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1034842 ·
Last close
$48.72
Market Cap
$910.08M
52W High
$52.24
52W Low
$24.95
ADV30
235,095
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 78,703,000 | 70,178,000 | 23,575,000 | 17,290,000 | 521,066,000 | 60,816,000 | 95,644,000 |
| Mar 2026 | 58,818,000 | 54,212,000 | 11,885,000 | 8,654,000 | 504,608,000 | 24,411,000 | 104,711,000 |
| Dec 2025 | 69,802,000 | 63,847,000 | 23,170,000 | 268,065,000 | 513,594,000 | 40,580,000 | 122,114,000 |
| Sep 2025 | 69,462,000 | 64,709,000 | 28,420,000 | 27,900,000 | 242,534,000 | 48,534,000 | 124,925,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$79,389,000
Investing CF
$-49,059,000
Financing CF
$-22,921,000
CapEx
$-26,000
Dividends Paid
—
Buybacks
$-4,251,000
EPS Diluted TTM
$16.32
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-997,097,000
Inventory
$14,367,000
Receivables
$56,041,000
ST Investments
$34,513,000
EBIT TTM
$91,381,000
Pretax Income TTM
$85,576,000
Interest Exp TTM
$5,805,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$276,784,992
EBITDA
$89,699,000
Free Cash Flow
$-31,758,876
Enterprise Value
$827,057,792
Total Cash
$95,329,000
Total Debt
$39,950,000
Shares Out
18,679,864
Trailing EPS
$16.89
Book Value
$22.81
ROE
126.9%
ROA
15.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 294,282,000 | 125,466,000 | 367,024,000 | 513,594,000 | 122,114,000 | 391,480,000 | 75,655,000 |
| Dec 2024 | 179,278,000 | 24,192,000 | 17,485,000 | 163,976,000 | 160,688,000 | 3,288,000 | 31,471,000 |
| Dec 2023 | 116,882,000 | -20,491,000 | -25,091,000 | 117,225,000 | 145,869,000 | -28,644,000 | -5,743,000 |
| Dec 2022 | 120,242,000 | -54,230,000 | -58,573,000 | 134,279,000 | 147,895,000 | -13,616,000 | -73,758,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$299,767,000
NetIncome TTM
$364,232,000
OpCashFlow TTM
—
Assets (Latest)
$504,608,000
Forward EPS
$4.94
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $36.00 · spot: $49.08 · call volume: 92 · put volume: 64
Expected Move to 2026-12-18:
±$9.65
(19.66%) —
implied range
$39.43 –
$58.73
· ATM straddle on $50.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANL | Adlai Nortye Group Ltd. | $910.97M | $15.51 | — |
| ALMS | ALUMIS INC. | $902.16M | $6.97 | — |
| MLTX | MoonLake Immunotherapeutics | $900.43M | $10.58 | — |
| JBIO | Jade Biosciences, Inc. | $899.90M | $14.15 | — |
| KURA | Kura Oncology, Inc. | $935.87M | $10.52 | — |
News headlines (Yahoo Finance, 1h cache)
Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope
2026-08-16 05:08 · Yahoo
Rigel (RIGL) Q2 2026 Earnings Call Transcript
2026-08-12 00:46 · Yahoo
Rigel Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
2026-08-05 12:30 · Yahoo
Rigel Pharmaceuticals Q2 Earnings Call Highlights
2026-08-05 02:03 · Yahoo
Rigel Reports Second Quarter 2026 Financial Results
2026-08-04 20:01 · Yahoo
Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant)
2026-07-29 20:30 · Yahoo
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
2026-07-28 12:05 · Yahoo
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-07-07 12:05 · Yahoo
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
2026-07-01 12:05 · Yahoo
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
2026-06-16 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.